HC Wainwright Reiterates Buy Rating on UroGen Pharma, Sets $75 Target
HC Wainwright reiterated its Buy rating and $75 price target on UroGen Pharma. The target implies 117.0% upside from the Oct. 16 close of $34.56.
Story updates
02:41:23 PM UTC
SquawkNews
UroGen Pharma Price Target Maintained With a $75.00/Share by HC Wainwright & Co.